Objectives: To evaluate the use of intravenous immunoglobulin (IVIG) in preventing relapses in patients with neuromyelitis optica (NMO) and its spectrum disorders (NMOSDs).
Methods: Six NMO/NMOSD patients who were treated with IVIG induction dose followed by 2- to 3- monthly infusions were retrospectively identified. Annualized relapse rates (ARR) and Expanded Disability Status Scale (EDSS) pre- and post-IVIG were recorded.
Results: Median number of relapses and median ARR significantly reduced from 8.0 to 1.0 and 0.75 to 0.15 (p<0.05) respectively. Median EDSS of 6.5 remained the same. Median duration of treatment was 4.0 years.
Conclusion: IVIG may be used to reduce the relapse frequency in patients with NMO/NMOSD.
Keywords: Intravenous immunoglobulin; Neuromyelitis optica; Neuromyelitis optica spectrum disorder; Relapse rate.
Copyright © 2015 Elsevier B.V. All rights reserved.